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1  | INTRODUC TION
Dermatophytosis is a superficial fungal infection of keratinized struc-
tures caused by specific filamentous fungi named dermatophytes. In 
humans, the incidence of dermatophytosis is elevated and continu-
ously increasing, rendering it a public health concern. The pathogeny 
of dermatophytosis remains poorly understood, partly due to the 
difficulties to set up a relevant model allowing the study of both the 
invasion of keratinized structures by fungi, and its impact on host tis-
sue architecture and functions. Recently, the development of human 
cultured skin equivalents has led to some advances. This review aims 
to summarize current knowledge about dermatophytosis and then 
focuses on in vitro models to investigate the alterations of the epi-
dermal barrier in response to fungal infection.
2  | DERMATOPHY TOSIS AND 
DERMATOPHY TES
Dermatophytosis is an infection of superficial keratinized 
epidermal layers, as well as hairs and nails, which is caused by 
keratinolytic filamentous fungi named dermatophytes.[1] Numerous 
dermatophyte species are grouped according to their ecological 
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Abstract
Fungal infections of the skin, known as dermatophytoses, are initiated at the epider-
mal barrier and lead to dysfunctions of the stratum corneum and cornified skin ap-
pendages. Dermatophytosis affects a significant part of the human population and, 
despite the availability of effective treatments, its prevalence is still increasing. 
Numerous dermatophyte species are able to induce lesions in both animals and hu-
mans, with different clinical pictures and host inflammatory responses. The under-
standing of the infectious process and of tissue responses has been impeded by 
discrepancies between observations in vivo or in research models. Indeed, cells cul-
tured as monolayers do not undergo the keratinization process required to study the 
adherence and invasion of dermatophytes. Animal models lack relevance to study 
human dermatophytosis because of species- specific differences in the development 
of lesions and inflammatory responses. This review focuses on the recent develop-
ment of cultured human skin equivalents, which partly overcomes those limitations 
and allows improved understanding of the pathogenesis of dermatophytosis in 
human being, especially the impacts of infection on epidermal barrier integrity.
K E Y W O R D S
epidermal barrier, fungal infection, model of dermatophytosis, reconstructed human epidermis, 
trichophyton rubrum
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niches. Anthropophilic dermatophytes rely mostly on human skin 
for growth and dissemination in the environment and represent 
a threat for humans only, as they rarely infect other organisms. 
Zoophilic species select preferred animal hosts but can frequently 
infect other species including humans. Geophilic dermatophytes 
feed on keratinized wastes found in the soil and rarely become 
pathogenic. Dermatophytes were previously classified according 
to morphological and physiological characteristics in culture, 
and to clinical features of the lesions in humans or animals.[1-3] 
Genome sequencing, especially analysis of the polymorphisms 
inside the variable rDNA regions known as internal transcribed 
spacers (ITS), has provided phylogenetic criteria for improved 
species identification.[4] A revised classification of dermatophytes 
was proposed,[5-7] based on DNA sequences of five different loci, 
including ITS, on morphology and physiology in culture, and on geo- , 
zoo- or anthropophilic ecology (Table 1). This review is concerned 
with anthropophilic and zoophilic dermatophytes frequently 
responsible for human infections.
Dermatophytosis is responsible for 3%- 4% of dermatological 
cases and is the most common fungal infection in humans, with a 
prevalence estimated around 20%- 25%.[8,9] In addition, its preva-
lence is continuously raising due to increased risk factors such as 
sport activities, type 2 diabetes, vascular diseases or ageing. Modern 
mobility further increases the dissemination of anthropophilic 
dermatophytes that extend in previously poorly affected geograph-
ical areas.[10,11] Among the species capable of infecting human skin, 
Trichophyton rubrum is the most frequently involved, being respon-
sible for 50%- 90% of dermatophytoses in humans.[9,12] The annual 
health expense cost of dermatophytosis is estimated to more than 
500 million of US dollars.[13]
2.1 | Dermatophyte infections induce various 
clinical pictures
The clinical signs of dermatophytosis result from both the 
degradation of keratinized tissues caused by fungal processes, as 
well as from the specific immune response of the infected host. 
Zoophilic species, probably less adapted to human hosts, generate 
more severe inflammatory responses than anthropophilic 
species.[6,14] Usual signs include dryness, desquamation, cracks 
and erythema of the skin of the feet, scalp or other body locations. 
Infections in hairless areas and nails, principally due to Trichophyton 
rubrum and Trichophyton interdigitale, are the most frequent in 
industrialized countries. Scalp infections, mainly observed in 
developing countries, are preferentially due to Microsporum canis, 
Trichophyton tonsurans and Trichophyton violaceum.[9] For instance, 
failure to adequately disinfect the hair cutting tools favours the 
dissemination of dermatophytes.[15]
TABLE  1 Main species of dermatophytes[5,7–9,14,16,23]
Species (former 
taxonomy) Ecological niche (preferred host)
Clinical picture in 
humans Epidemiology
Epidermophyton floccosum Anthropophilic (human) Tinea pedis 
Tinea unguium 
Tinea cruris
Microsporum audouinii Anthropophilic (human) Tinea capitis 
Tinea corporis
Mainly found in sub- Saharan Africa
Microsporum canis Zoophilic (cat, dog) Tinea capitis 
Tinea corporis
Nannizia fulva 
(Microsporum gypseum)
Geophilic Tinea capitis (rarely) Most common geophilic species
Nannizia gypsea 
(Microsporum gypseum)
Nannizia incurvata 
(Microsporum gypseum)
Trichophyton benhamiae 
(Arthroderma benhamiae)
Zoophilic (guinea pig) Tinea capitis 
Tinea corporis
Trichophyton interdigitale Anthropophilic (human) Tinea pedis 
Tinea unguium
Second most common species worldwide
Trichophyton 
mentagrophytes
Zoophilic (dog, cat, rabbit) Tinea corporis 
Tinea capitis
Trichophyton rubrum Anthropophilic (human) Tinea pedis 
Tinea unguium 
Tinea corporis
Most common species worldwide
Trichophyton tonsurans Anthropophilic (human) Tinea capitis 
Tinea corporis
Trichophyton violaceum Anthropophilic (human) Tinea capitis 
Tinea corporis
Most important species in Africa
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In most human cases, dermatophytosis lesions remain super-
ficial, confined to the epidermis. Histologically, dermatophytic 
lesions exhibit fungal components (arthroconidia, filaments) re-
stricted to the cornified layer of immunecompetent patients. 
Intercellular oedema and acanthosis, a thickening of the epidermis 
that results from increased keratinocyte proliferation, are some-
times observed.[16]
Unfrequently, dermatophytes invade the dermal tissue, partic-
ularly after local trauma in patients with chronic infection.[17,18] In 
immune- deprived patients, dermatophytosis may involve subcu-
taneous tissues and even deep organs, possibly becoming a life- 
threatening disease in the absence of appropriate treatment.[19,20]
Although dermatophytosis is usually not a severe condition, 
its impacts on the quality of life are significant. In addition to local 
pain and unpleasant feelings around lesions, patients suffer psy-
chologically due to aesthetic features of lesions and their social 
consequences.[21,22]
2.2 | Contamination by dermatophytes is favoured 
by risk factors and genetic predispositions
The dissemination of dermatophytes in humans occurs by direct 
contact with an infected patient or animal. It can also result from 
contact of the skin with contaminated items, as fungal arthroconidia 
remain infectious for more than 1 year in the environment.[23]
Numerous risk factors favour dermatophytosis, illustrating the 
importance of maintaining effective epidermal and immunological 
barriers to protect cutaneous tissues. Decreased epidermal bar-
rier efficiency, induced by scratches, nail alterations or low level of 
sebum secretion before puberty, as well as elevated environmental 
humidity, may contribute to promote dermatophytosis.[24] Impaired 
peripheral blood circulation due to age or other causes, with con-
secutive diminished nutrient availability, reduced oxygenation, and 
delay in migration of immunecompetent cells or in production of an-
timicrobial peptides (AMP) at the site of infection may favour the 
infectious process. As a result of alterations of peripheral blood cir-
culation and nerve endings, diabetes leads to an almost threefold 
increased risk of dermatophytosis, especially foot and nail tinea.[25] 
Moreover, frequent close contacts with domestic, livestock or wild 
animals are linked to susceptibility to dermatophytosis.[24] Sport 
practice, especially in indoor facilities and swimming pools, in-
creases the barefoot exposure to potentially contaminated areas.[26] 
Excessive foot perspiration in closed shoes is also detrimental.[10] 
These factors are probably responsible for an elevated prevalence 
of dermatophytosis from 15% in the general population to 70% in 
subjects that engage in regular sport practice.[27-29]
Since the 1990s, links between the familial history and the sus-
ceptibility to dermatophytosis have been reported,[30,31] and several 
genetic predisposition factors have been identified.[32] Some HLA 
haplotypes protect against, whilst others increase the risk of derma-
tophytosis.[33-35] Mutations in gene CLEC7A, which encodes protein 
dectin- 1 that binds to fungal β- glucans,[36] as well as mutations in 
the signalling pathways involved in the immune antifungal response, 
such as CARD9 and STAT3,[37,38] are linked to increased occurrence of 
dermatophytosis. More recently, low copy numbers of gene DEFB4, 
encoding the antimicrobial peptide (AMP) β- defensin- 2, were shown 
to increase susceptibility to dermatophytosis.[39] AMPs are involved in 
the skin defence against pathogens, including bacteria, virus or fungi, 
through direct antimicrobial activities, as well as through immunomod-
ulatory effects and reinforcement of the epidermal barrier.[40,41] The 
AMP β- defensin- 2, β- defensin- 3, RNase 7, S100A7 and cathelicidin 
LL- 37 inhibit in vitro the growth of various dermatophytes species, in-
cluding T. rubrum, and are overexpressed in response to the presence 
of dermatophytes in monolayer cultures of keratinocytes, and in skin 
biopsies from patient with dermatophytosis.[42-44]
3  | DERMATOPHY TE BIOLOGY AND 
MECHANISMS OF CUTANEOUS INFEC TION
Like other eukaryotic cells, cells of dermatophytes are characterized 
by the presence of a nucleus and organelles, including mitochon-
dria and vacuolar membrane- limited compartments involved in the 
storage, distribution and recycling of metabolites.[45] In the fungal 
cell membrane, ergosterol replaces cholesterol, which is specific to 
animal cells, to modulate fluidity of the phospholipid bilayer and to 
serve as a precursor of other cell components. The ergosterol syn-
thesis pathway is thus regarded as one particularly interesting target 
for antifungal treatments.[46-48] Fungal cells are further surrounded 
by a cell wall responsible for mechanical resistance, cell shape and 
rigidity.[49,50] The cell wall plays a role in adhesion between fungi 
themselves, and between fungi and other living cells. It is composed 
of polysaccharides such as β- glucans and chitin, and glycoproteins.[51] 
Chitin chains are interconnected by hydrogen bonds to form several 
layers and are covalently bound to networked β- glucans and glyco-
proteins on their external side.[45,52-54] Components and thickness 
of fungal cell walls vary between species. Still poorly characterized 
in dermatophytes, it is composed of chitin, β- glucans, mannans and 
galactomannans.[51,55]
3.1 | Dermatophytes are filamentous fungi and 
produce two types of spores
Dermatophytes are filamentous fungi, which mean that they 
develop into tubular structures named hyphae, made of 
interconnected aligned fungal cells bordered by an uninterrupted 
wall. The hyphae are regularly divided into cell compartments by 
septa made of peripheral rings with a composition similar to that 
of the cell wall. Pores through these septa allow communication 
between cytoplasm of multiple cell compartments along the entire 
hypha.[45]
Contrary to active hyphae, the spores are quiescent unicellular 
elements with low metabolic activity.[45] Their cell wall is thicker 
than that in hyphae, providing an extreme mechanical resistance, 
and their high lipid and glycogen content, serves as energy storage 
for eventual reactivation. Spores are physiologically designed to 
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disperse in the environment and to survive in adverse conditions. 
Upon improvement of environmental conditions, spores reactivate 
and develop into new hyphae.
The anthropophilic dermatophytes undergo asexual reproduction 
using mitosis.[56] Hyphae can produce two types of spores through 
formation of conidia or arthroconidia.[45] Conidia result from lateral 
or terminal budding of a hypha; microconidia are single individuals, 
whilst macroconidia comprise several conidia attached together that 
result from successive budding events. In contrast, arthroconidia 
are produced through the fragmentation of hyphae at site of septa. 
Conidia are solely produced in vitro on Sabouraud medium, whereas 
arthroconidia are produced by dermatophytes in vivo, indicating that 
the environment is critical to the type of sporulation and growth.[57]
Fungal colonies are formed from activated spores, when they 
encounter favourable conditions.[45,58] Regarding pathogenic der-
matophytes, those conditions are fulfilled when arthroconidia ad-
here to adequate tissues of a tolerant species. First, spores swell by 
rehydration and form new cell wall components in a nonpolarized 
way. Simultaneously, synthesis of nucleic acids and proteins con-
curs to create new emerging tubular structures, creating new cell 
content as well as an elongating and thickening cell wall. When the 
cell volume becomes large enough, nuclear division occurs and a 
septum appears to separate the cells into two interconnected com-
partments, creating a hypha. Each compartment may continue this 
process, building new compartments and elongating the hyphae. 
In this way, hyphae are able to grow, progressively elaborating di-
verging ramifications and ultimately large colonies. Interconnected 
hyphae created from one spore are named the mycelium.
3.2 | Dermatophytes infect the skin through 
different steps
When human skin is infected by dermatophytes, three steps can be 
recognized.[59,60] First arthroconidia adhere to the host epidermis 
through specialized proteins present on the fungal surface[61,62] and 
proteases released by fungi, such as subtilisin 3.[63-66] In a second 
step, called germination, arthroconidia detect favourable conditions 
and initiate the reactivation of metabolic activity and their growth 
into hyphae.[58] During the third step, referred to as invasion, hyphae 
produced from the germinating tubes invade the epidermal cornified 
layer, whilst digesting keratin into small peptides and amino acids.[67] 
Finally, the hyphae start producing new arthroconidia that are re-
leased locally to infect other individuals or body sites. The steps of 
skin infection by dermatophytes, as well as the impacts on the epi-
dermal tissue, are illustrated in Figure 1.
4  | IN VITRO MODEL S OF 
DERMATOPHY TOSIS
Several experimental models have been developed to characterize 
the mechanisms whereby dermatophytes to invade host tissues, 
to understand the immune response and to evaluate the efficacy 
of antifungal treatments. For instance, suspension of isolated 
cornified keratinocytes,[68] fragments of cornified layer isolated by 
tape- stripping methods[69] and pieces of nails or hairs[67] have been 
used. These protocols are convenient to grow dermatophytes, but 
are devoid of living keratinocytes and therefore cannot be used to 
model the epidermal response.
To address those limitations, keratinocytes cultured in mono-
layers[70-73] and neutrophils[74] have been used to observe the cell 
response to the presence of dermatophytes, through the detection 
of released cytokines and AMPs. However, as keratinocytes cul-
tured in submerged conditions do not proceed to full keratinization, 
these models are not adequate to study the adhesion and invasion 
by dermatophytes.
In parallel, in vivo animal models, such as guinea pig[64] or 
mouse,[75] have been explored. However, the severity of lesions and 
the extent of inflammatory responses vary considerably accord-
ing to the host and the dermatophyte species.[6,14] A consistent in 
vivo model of infection should thus be developed using the natu-
ral host. As T. rubrum does not naturally infect non- human spe-
cies, the development of an animal model is not fully relevant.[76] 
Despite those limitations, in vivo models of T. rubrum dermatophy-
tosis using guinea pig[77] or mouse[78,79] have been reported, but the 
protocols required multiple application of spores or abrasive treat-
ments to initiate some cutaneous infection. Those in vivo models 
yielded useful information about pathogenic mechanisms, such as 
F IGURE  1 Schematic summary of epidermal infection by the 
anthropophilic dermatophyte Trichophyton rubrum. One hour after 
infection by contact, arthroconidia adhere to the host epidermis 
by a complex mechanism involving fungal secreted proteases 
and surface molecules. After 4 h, germination has started and 
arthroconidia produce germ tubes which grow to form segmented 
hyphae detected on the epidermal surface from the sixth hour of 
infection. As soon as 24 h after application of arthroconidia on 
the epidermis, and for the 3 d following infection, hyphae invade 
the cornified layer by progressing through intercellular spaces 
and inside corneocytes, most likely as a result of degradation of 
corneodesmosomes, extracellular lipid matrix and intracellular 
keratin. On the fourth day of infection, hyphae reach the 
granular layer. At this stage, integrity of the epidermal barrier is 
lost in response to alteration of tight junctions. Simultaneously, 
keratinocytes exhibit enhanced expression and release of 
proinflammatory cytokines and antimicrobial peptides, which will 
then be responsible for control and eventual resolution of the 
infection
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the role of fungal keratinases[64,80,81], about immune responses of 
the host,[75,79] and allowed testing of antifungal compounds.[77,82,83] 
Cutaneous explants freshly isolated from various species including 
humans.[64-66,84-86] represent an interesting alternative. However, 
their limited availability, together with the large variability between 
the different donors, severely restrict their use. To palliate those lim-
itations, cultured reconstructed human epidermis was used to study 
the development and analysis of T. rubrum dermatophytosis.
Reconstructed epidermis or epidermis on collagen lattice including 
fibroblasts mimics closely superficial cutaneous tissues, as they exhibit 
a cornified layer at their air- liquid interface, like in vivo. They allow 
studies of the interactions between pathogens and epidermal kera-
tinocytes, and of subsequent barrier alterations. Studies on Candida 
albicans[87] or on percutaneous migration of helminths[88] have demon-
strated the potential of reconstructed tissues to investigate safely and 
ethically some infectious processes that occur in human skin.
Several models of dermatophytosis on reconstructed human 
epidermis (RHE) have been reported. In 1995, a first report con-
firmed the efficacy of terbinafine as an antifungal compound in a 
reconstructed tissue.[89] More recently, two models of dermatophy-
tosis based on commercially available reconstructed skin models, 
EpiDerm (MatTek)[73] and Episkin®,[90] have been published. Both 
utilized conidia as infectious material. However, conidia have never 
been observed in dermatophytosis lesions in patients, where only 
arthroconidia are identified.[57] Therefore, the use of arthroconidia 
seems more adapted, and the production of arthroconidia in vitro 
was carried out, using a culture medium poor in nutrients, combined 
with an elevated CO2 partial pressure.
[91] An in vitro model of derma-
tophytosis using arthroconidia and reconstructed feline epidermis 
was set up to evaluate the efficacy of antifungal molecules[92] and al-
lowed demonstration of a crucial role of the fungal protease subtili-
sin 3.[63] We recently illustrated the use of arthroconidia in an in vitro 
model of RHE infection with different strains of T. rubrum, as well 
as with zoophilic Microsporum canis and Trichophyton benhamiae.[93] 
Interestingly, RHE infection by dermatophytes can be monitored in 
tissue sections using histochemical periodic acid- Schiff (PAS) stain-
ing of chitin, a component of the fungal cell wall (Figure 2). Prior to 
PAS, digestion of glycogen by α- amylase was carried out to suppress 
glycogen staining in suprabasal keratinocytes.[93] This morphological 
approach, together with the quantitation of fungal elements using 
PCR amplification of dermatophyte 18S rDNA, proved sensitive 
enough to localize dermatophytes in RHE and to monitor the infec-
tion over time. In this system, the adhesion of arthroconidia to RHE 
happened within 1 hour and a topical application of miconazole was 
able to prevent or abolish fungal infection.[93]
5  | RECONSTRUC TED HUMAN EPIDERMIS 
ALLOWS TO CHAR AC TERIZE BARRIER 
ALTER ATIONS UPON INFEC TION
Upon dermatophyte infection of RHE, signs of leakage of the barrier 
were observed 4 days or later after infection. Achterman et al[73] 
described release of LDH activity from RHE (EpiDerm from MatTek) 
after culture with conidia from various dermatophyte species. Of 
interest, this release did not occur after the exposure of RHE to heat- 
killed fungi. LDH release becomes obvious when dermatophytes 
remain in close contact with the epidermal tissue for at least 4 days. 
A similar timeframe allowing tissue invasion followed by destruction 
of the cultured epidermis after 10 days was confirmed by Liang 
et al[90] who used the EpiSkin® model, which includes dermal 
components, to probe T. rubrum infection. Their study also showed 
that conidia applied at low density were less prone to extend into 
deep layers after 4 days of infection. Using our “Open Source” RHE 
model recommended for nonanimal testing due to its openness, 
transparency and collaborative development,[94-97] it appeared that 
several dermatophyte species and strains remained restricted to 
the cornified layer after 4 days of infection at densities selected for 
infection.[93]
To understand the response of epidermal tissue to dermatophyte 
infection, cell signalling and cytokine release have been assayed 
upon infection of RHE. Even if immune components are absent 
from the RHE models investigated so far, the robust responses of 
keratinocytes suggest that they sense the presence of hyphal fungi 
upon contact. This led us to monitor the decrease in the barrier ef-
ficiency during T. rubrum infection, to characterize the invasion of 
the cornified layer by ultrastructural analysis and to study inflamma-
tory or antimicrobial responses.[98] The epidermal barrier was found 
F IGURE  2 Progressive invasion of reconstructed human 
epidermis (RHE) by different dermatophyte species. A, RHE was 
infected by topical application directly on the cornified layer of 
Trichophyton rubrum IHEM 13894, Microsporum canis IHEM 21239 
or Trichophyton benhamiae IHEM 20163 arthroconidia, respectively, 
at densities of 1700 per cm2, 17 000 per cm2 and 53 per cm2. 
RHE was then processed 1, 2, 3, 4 d or 5 d after infection for 
histology, using periodic acid- Schiff (PAS)- staining after α- amylase 
treatment and hemalun counterstaining of tissue sections. B, RHE 
infected by topical application of Trichophyton rubrum IHEM 13894 
arthroconidia was processed 1 and 4 d after infection for histology, 
using HE- staining of tissue sections. Scale bars: 20 μm
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deficient after 4 days of infection, by (a) monitoring the transepi-
thelial electrical resistance through RHE; (b) estimating the Lucifer 
yellow outside- in permeation using fluorimetry or histology; and (c) 
assessing inside- out diffusion of biotin upwards through the RHE. 
Accordingly, tight junctions were disorganized when the barrier 
efficiency was impaired. In addition, signs of activation of defense 
mechanisms confirmed potential roles of keratinocytes. Of inter-
est, p38 MAPK inhibitor PD169316 hampered the development of 
T. rubrum infection on RHE, indicating that this signalling pathway 
is somehow involved during dermatophytosis, at least in vitro.[98] In 
this context, it is worth noting that activation of p38 MAPK in ep-
ithelial cells has recently been associated with alterations of tight 
junctions.[99] Altogether, data obtained so far result in identification 
of the MAPK p38 signalling pathway as a major component of epi-
dermal response.[73] Thus, we hypothesized that the p38 pathway 
could induce or modulate the immune response leading to expres-
sion and release of proinflammatory genes and proteins.[73]
6  | LIMITATIONS AND PERSPEC TIVES 
OF IN VITRO INVESTIGATION OF 
DERMATOPHY TOSIS
In vitro modelling of dermatophyte infection allows investigation 
of the mechanisms involved, by providing conditions to grow these 
highly selective fungi in an environment similar to what they encoun-
ter in vivo. Human skin equivalents cultured at an air- liquid interface 
produce a functional cornified layer that allows the study of adhe-
sion and invasion by dermatophytes, and contains living keratino-
cytes able to react to infection. These models have the advantage 
to mimic infection of the human skin without ethical limitations. 
They seem more appropriate than in vivo animal models due to host- 
related differences in the severity of lesions and in inflammatory 
responses. The fact that skin equivalents are composed solely of 
keratinocytes allows to highlight their specific roles.
On the other hand, in vitro three- dimensional RHE models suffer 
some limitations, notably the lack of immune cells, hampering in-
vestigations of immune responses. The absence of microbiome and 
absence of sebum, as well as the culture conditions characterized by 
the absence of friction and by an elevated relative humidity, prob-
ably act together to limit the normal epidermal barrier efficiency, 
rendering the human skin equivalents more susceptible to dermato-
phyte infection than their in vivo counterparts.
Altogether, data obtained using in vitro and in vivo models of der-
matophytosis allow to outline key steps of dermatophyte infection 
of human epidermis (Figure 1). Upon seeding with a defined inocu-
lum, adhesion of arthroconidia to the cornified layer happens 1 hour 
after contact[93] by a complex mechanism involving fungal secreted 
proteases, such as subtilisin 3,[63-66] and surface molecules.[61,62] 
Four hours after infection, germination starts. Arthroconidia pro-
duce germ tubes which grow to form segmented hyphae detected on 
the epidermal surface from the sixth hour of infection.[69,90,93] After 
24 hours, and for the 3 days following infection, hyphae invade the 
cornified layer by progressing through intercellular spaces and inside 
corneocytes, most likely as a result of degradation of corneodesmo-
somes, extracellular lipid matrix and intracellular keratin.[69,84,90,93] 
On the fourth day of infection, hyphae reach the granular layer. At 
this stage, integrity of the epidermal barrier is lost in response to 
alteration of tight junctions.[93] Simultaneously, keratinocytes ex-
hibit enhanced expression and release of proinflammatory cytokines 
and AMP,[73,93] responsible for control and eventual resolution of 
the infection through activation of the immune system. Because 
studies in vitro[70,71,73,74,100,101] and in vivo[75,79] revealed a release 
of pro- Th1 (IL- 12, IFNγ) and pro- Th17 (IL- 1β, TGF- β, IL- 6) cytokines 
upon dermatophyte infection, a cooperation between these two 
pathways is likely to provide protective response against dermato-
phytosis. However, in vitro studies which relied on the stimulation 
of immune cells by spores or components of dermatophytes are not 
suited to study interactions between keratinocytes and immune 
cells. On the other hand, studies of animal models cannot assess 
the human immune response to dermatophytosis. To study the im-
mune system activation, human models including epidermal tissue 
and cells of the immune system are required. The development of a 
human skin equivalent comprising both keratinocytes and immune 
cells will require major technical improvements, for example, design 
a matrix that allows immune cells migration and/or define a culture 
medium for optimal growth of both cell types. Progress has recently 
been made in that direction. A reconstructed skin equivalent was 
cocultured with macrophages below the culture insert to measure 
cytokines production by macrophages in responses to topical appli-
cation of LPS.[102] Van den Bogaard et al[103] designed a coculture of 
human skin equivalents populated with T cells. In this model, pre-
activated T cells, added underneath the reconstructed tissue, were 
able to migrate into the dermis and to induce production of cyto-
kines and AMP by keratinocytes. Adjustment of this model would 
be very helpful to assess the behaviour of naïve T cells and the 
crosstalk with keratinocytes upon infection with dermatophytes. 
Another coculture model was developed to evaluate the transepi-
thelial migration of neutrophils through lung epithelial cells cultured 
in monolayer, in responses to topical infection by Escherichia coli.[104] 
That model could potentially be adapted to skin equivalent infected 
with dermatophytes. A sophisticated method designed to assess the 
migration of dendritic cells in responses to sensitizing substances[105] 
could also be used to monitor the release by keratinocytes of factors 
influencing dendritic cells.
In conclusion, human skin equivalents currently represent a reli-
able model to study the pathogenic mechanisms of human dermato-
phytosis, such as adhesion, invasion and disruption of the epidermal 
barrier. Further improvements, especially development of coculture 
with immune cells, would broaden their relevance to the human in 
vivo context.
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